Last updated on October 2018

Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2

Brief description of study

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.

Clinical Study Identifier: NCT02945228

Contact Investigators or Research Sites near you

Start Over

AbbVie_Japan PMOS_Desk

Sawada Hepatology & Gastroenterology /ID# 165255
Takaraduka, Japan